Vertex Pharmaceuticals Incorporated: Pain trials
The registry lists 26 Pain studies with Vertex Pharmaceuticals Incorporated as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 24Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute PainCompletedNCT05661734Phase 3Results posted
- Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy ParticipantsCompletedNCT07570069Phase 1
- Evaluation of Pain Treatment After Total Knee ArthroplastyCompletedNCT07538570Phase 4
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsCompletedNCT07378865Phase 1
- A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral DoseCompletedNCT06886269Phase 1
- A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult PanelistsCompletedNCT06834009Phase 1
- Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female ParticipantsCompletedNCT06820307Phase 1
- A Phase 1 Dose Escalation Study of VX-973 in Healthy ParticipantsCompletedNCT06615570Phase 1
- Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy AdultsCompletedNCT06523595Phase 1
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993CompletedNCT06508762Phase 1
- A Microneurography Study of NaV1.8 Inhibition in Healthy AdultsCompletedNCT06420765Phase 1
- A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy AdultsCompletedNCT06394167Phase 1
- A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy AdultsCompletedNCT06392659Phase 1
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of SuzetrigineCompletedNCT06336096Phase 1
- A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993CompletedNCT06226454Phase 1
- A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsCompletedNCT05866055Phase 1
- A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548CompletedNCT05851157Phase 1
- A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy ParticipantsCompletedNCT05818852Phase 1
- Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal ImpairmentCompletedNCT05704556Phase 1
- A Phase 1 Dose Escalation Study of VX-993 in Healthy ParticipantsCompletedNCT05653323Phase 1
- Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy ParticipantsCompletedNCT05635110Phase 1
- Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT05560464Phase 1
- A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and DigoxinCompletedNCT05541471Phase 1
- A Phase 1 Dose Escalation Study of VX-708 in Healthy ParticipantsCompletedNCT05518734Phase 1
- A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548CompletedNCT05455502Phase 1
- A Microneurography (MNG) Study of VX-150 in Healthy ParticipantsCompletedNCT05418712Phase 1